Condition: Cavernous Malformation, Cerebral · Cavernous Angioma · Cavernous Hemangioma · Sponsor: yuanli Zhao
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.
This description comes directly from the study's public registry record.
Li Ma, MD, PhD · 86-010-59978317 · marygl@hotmail.com
Yuanli Zhao, MD · 86-010-59978478 · zhaoyuanli@126.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Peking University International Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04076449